Planview continued strong momentum through 2024, marked by customer growth, product innovations and industry recognition.

In a healthcare market brimming with potential, DarioHealth Corp. * is quietly emerging as a standout player, combining cutting-edge technology with proven outcomes. Looking at recent achievements, it ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

According to Grand View Research, the European and Middle Eastern drug screening markets are projected to grow significantly by 2030, with Europe expected to reach $3.6 billion and the Middle East and ...